Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.46 HKD -9.9% Market Closed
Market Cap: 2.4B HKD
Antengene Corporation Ltd
/
Cash Flow Statement
/
Free Cash Flow

Antengene Corporation Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Antengene Corporation Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Free Cash Flow
-¥778.9m
CAGR 3-Years
-29%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Free Cash Flow
¥2.9B
CAGR 3-Years
44%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Free Cash Flow
¥1B
CAGR 3-Years
47%
CAGR 5-Years
-8%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Free Cash Flow
¥6.3B
CAGR 3-Years
64%
CAGR 5-Years
17%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Free Cash Flow
¥4.4B
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
14%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Free Cash Flow
-¥1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2.3B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.79 HKD
Overvaluation 48%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Antengene Corporation Ltd's Free Cash Flow?
Free Cash Flow
-778.9m CNY

Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Free Cash Flow amounts to -778.9m CNY.

What is Antengene Corporation Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-47%

Over the last year, the Free Cash Flow growth was -16%. The average annual Free Cash Flow growth rates for Antengene Corporation Ltd have been -29% over the past three years , -47% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.